

SFB/TR 209 LIVER CANCER

New mechanistic and therapeutic concepts in a solid tumor model

Dear SFB/TR 209 - members,

Our Collaborative Research Center is marching towards the mid-term of its first funding period. The projects are now running at full capacity and we are happy about a number of excellent publications. The seminars are running successfully at all three locations, as well as the Gerok stipends and all other SFB measures. Therefore, we can look back to a successful year 2018 of which we can be proud of. Based on these accomplishments, the new year is of particular importance for the success of the SFB/TR 209, as it also represents the basis for a successful application for the next funding period. In this spirit, we wish you all a happy and successful new year

Yours,







P. Schirmacher

N. Malek

M. P. Manns

LATEST NEWS

RETREAT 2019

We already look forward to the next retreat. It will take place in the week 5-7th June 2019 in Fulda.

The **junior** retreat starts at 10:30h on **Wednesday**, **June 5**th. The planning has already started and the organizing committee (K. Woll together with one representative of the PhD-students from each side) is open for further ideas. Please contact K. Woll.

The general retreat starts **Thursday**, **June 6**th, 2019 at about 10:30h and will last till **Friday**, **June 7**th, 2019 early afternoon.

HCC CONFERENCE 2020

As intended and applied for, we will organize an international HCC conference in the 3rd year of our SFB/TR 209. The conference will take place on July 6-8th, 2020 at the DKFZ conference center in Heidelberg.

Please label this date already as a mandatory conference in your calender.

PROJECT AREA

Due to his new appointment at the University hospital in Greifswald in 2017, funding of Prof. S. Singers project B04 ended 2018. With the new year the project is finally terminated and therefore no longer part of the SFB/TR 209. Nevertheless, collaborations are still ongoing and we are wishing him all the best for a successful future.

The application of the new project B08 (Longerich/Pellegrino) has been evaluated positively by the DFG. The project started in December 2018 and we are happy to have it in our consortium. The project and its team will be introduced during the next retreat.

GEROK STIPENDS

Gerok stipends are in place at all three sites according to the regulations. The Gerok stipend from Tübingen, Dr. K. Büringer already presented his progress at the last retreat. Since November 2018 we have a new Gerok stipend in Hannover, Tiago de Castro working in project C01 (Vogel). He will present his project during the next retreat (5-7th June 2019).

HOMEPAGE

The homepage of the SFB/TR 209 is available under www.livercancer.de. Please let us know your ideas and suggestions and keep us informed about any changes and announcements concerning your project on the



SFB/TR 209 LIVER CANCER

New mechanistic and therapeutic concepts in a solid tumor model

homepage. The logo can be downloaded from the site. Please use it wherever possible.



SERVICE PROJECTS

INF-Data analysis: Access to TCGA data only for applying sites (TÜ and MHH) available; in HD the Institute of Pathology and DKFZ have access to raw data of TCGA; SOPs for application to access will be provided; contact to the HiGHmed consortium could be beneficial.

INF-Cell lines: The list of available cell lines can be downloaded in the internal area of the SFB/TR 209 homepage or requested from K. Woll.

UPCOMING CONFERENCES

GI-ASCO: 17.-19.01.2019, San Francisco HCC-Summit: 14.-16.02.2019, Lisbon

APASL: 20.-24.02.2019, Manila GASL: 22./23.02.2019, Heidelberg AACR: 29.03.-03.04.2019, Atlanta

ILC: 10.-14.04.2019, Vienna

ASCO: 31.05-04.06.2019, Chicago DGP: 13.-15.06.2019, Frankfurt Hep Net: 28./29.06.2019, Hannover

ILCA: 20.-22.09.2019, Chicago

ESMO: 27.09. – 01.10.2019, Barcelona DGVS: 02.-05.10.2019, Wiesbaden

AASLD: 11/2019, Boston

DKK: 19. -22.02.2020, CityCube Berlin

SFB/TR 209 HCC-Conference: 06.-08.07.2020, Heidelberg

RECENT TOP PUBLICATIONS

Lohmann V. (2018) Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med Microbiol Immunol. 2018 Oct 8. doi: 10.1007/s00430-018-0566-x. (project **A02**)

Seehawer M, Heinzmann F, D'Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, Rozenblum N, Kang TW, Chawla R, Buch T, Vucur M, Roth M, Zuber J,

Luedde T, Sipos B, **Longerich T, Heikenwälder M**, Wang XW, Bischof O, **Zender L** (2018) Necroptosis microenvironment directs lineage commitment in liver cancer. Nature.;562(7725):69-75. (project **A03**, A04, B08). Correction in Nature. 564(7735):E9. (project **A03**, A04, B08)

Goeppert B, Toth R, **Singer S**, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, **Schirmacher P**, Plass C, Weichenhan D, **Roessler S** (2019) Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology. 2019 Jan 7. doi: 10.1002/hep.30493. (projects **B01**, B04)

Breinig M, Schweitzer AY, Herianto AM, Revia S, Schaefer L, Wendler L, Cobos Galvez A, **Tschaharganeh DF** (2019) Multiplexed orthogonal genome editing and transcriptional activation by Cas12a. Nat Methods. 16(1):51-54. (project **B05**)

Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss K-H, **Breuhahn K**, Mehrabi A, Weber T F, Wilkens L, **Straub B. K.**, Rosenwald A, Schulze F, Brors B, Fröhling S, **Pellegrino** R, Budczies J, **Schirmacher P**, Stenzinger A (2019) RSPO2 gene rearrangement — a powerful driver of β -catenin activation in liver tumours *Gut* 10.1136/gutjnl (projects B08, B03, AP)

Saborowski A, Wolff K, Spielberg S, Beer B, Hartleben B, Erlangga Z, Becker D, Dow E L, Marhenke S, Woller N, Unger K, Schirmacher P, Manns M P, Marquardt J U, Vogel A, Saborowski M (2019) Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro. Hepatology Communications accepted (project B07; C01)

NEWS AND **A**CCOMPLISHMENTS

As of January 1st, 2019, M. P. Manns is President of Hannover Medical School (President and Member of the Presidium responsible for the Division of Research and Teaching) and will remain Director of the Department of Gastroenterology, Hepatology and Endocrinology until further notice.

V. Lohmann (project A02) received a prize endowed with 5.000 € for his scientific achievements in translational infection research from the DZIF (German Center for Infection Research).

K. Breuhahn (project B03) will be part of the SPP1782/2 of the DFG 'Epithelial intercellular junctions as dynamic hubs to integrate forces, signals and cell behaviour' with his project on "Connecting intercellular cell junctions



SFB/TR 209 LIVER CANCER

New mechanistic and therapeutic concepts in a solid tumor model

with Hippo/YAP pathway activity in hepatocytes and liver tumor cells" starting in January 2019.

A joint German-Egypt project of K. Breuhahn (project B03) and A. Abdelaziz (Newgiza University, Cairo) will be funded for three years by the DFG to further work on "Identifikation YAP/TAZ-regulierter nicht-kodierender RNAs (ncRNAs) im Leberkrebs".

M. Kriegsmann (Gerok Stipend in Heidelberg) received the Hochgesand-Preis for Pathology 2018 for his work on tumor typing by Matrix-assisted Laser Desorption/Ionization Imaging mass spectrometry on formalin-fixed paraffin-embedded tissue specimens.

Last year, T. Illig (INF-MHH) was one of the most cited scientists in the field of molecular biology and genetics (acc. to Web of Science).

FINANCIAL ISSUES

TRAVEL GRANTS

According to the application and granting each project has 2.000 € /year travel allowance for travel costs related to scientific issues of the respective SFB/TR 209 project. For reimbursement of your travel expenses please complete the form which can be downloaded from the internal area of our homepage or provided by K. Woll and send the original receipts together with the signed form to K. Woll.

In addition we ask you to provide us with information to which conferences you have contributed by presentation and represented the SFB/TR 209 for announcement in the newsletters and on or homepage.

PUBLICATION FUNDS

We have a common pool to support publications if the work published is related to the SFB/TR 209. Therefore, please always use the following phrase in your publications:

"This ... (work, research, etc.) was carried out with the support of the German Research Foundation (DFG) within project X, SFB/TR 209 "Liver Cancer"."

"Diese … (Arbeit, Forschung, etc.) wurde im Rahmen des von der Deutschen Forschungsgemeinschaft (DFG) geförderten SFB/TR 209 "Liver Cancer" (Projekt X) erstellt."

Please also here keep us updated about the latest publications also in advance for announcement in the newsletter and on our homepage.

Contact and General Coordination:

Dr. rer. nat. Katrin Woll Pathologisches Institut Im Neuenheimer Feld 224 69120 Heidelberg

Tel: +49/6221-56 39186 Fax: +49/6221-56 5251

Email: katrin.woll@med.uni-heidelberg.de



Secretary in Heidelberg

Silke Greiner
Pathologisches Institut
Im Neuenheimer Feld 224
69120 Heidelberg
Tel: +49/6221-56 4165

Fax: +49/6221-56 5251

Email: silke.greiner@med.uni-heidelberg.de



Secretary in Hannover

Petra Huber and Britta Köpping Carl-Neuberg-Str. 1 30625 Hannover Tel: ++49/511 32 6763

Email: Huber.Petra@mh-hannover.de Koepping.britta@mh-hannover.de



Secretary in Tübingen

Silke Abele Zentrum für Personalisierte Medizin Frondsbergstraße 23 72076 Tübingen

Tel: ++49/7071 29 82864 Email: silke.abele@med.uni-tuebingen

